JP2011503164A - 呼吸障害に関連する方法 - Google Patents
呼吸障害に関連する方法 Download PDFInfo
- Publication number
- JP2011503164A JP2011503164A JP2010533659A JP2010533659A JP2011503164A JP 2011503164 A JP2011503164 A JP 2011503164A JP 2010533659 A JP2010533659 A JP 2010533659A JP 2010533659 A JP2010533659 A JP 2010533659A JP 2011503164 A JP2011503164 A JP 2011503164A
- Authority
- JP
- Japan
- Prior art keywords
- pge
- ep3r
- mpges
- test substance
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 158
- 230000029058 respiratory gaseous exchange Effects 0.000 title claims description 130
- 208000008784 apnea Diseases 0.000 claims abstract description 115
- 239000002207 metabolite Substances 0.000 claims abstract description 87
- 208000023504 respiratory system disease Diseases 0.000 claims abstract description 83
- 208000033300 perinatal asphyxia Diseases 0.000 claims abstract description 54
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 claims abstract description 50
- 206010070511 Hypoxic-ischaemic encephalopathy Diseases 0.000 claims abstract description 36
- 208000009973 brain hypoxia - ischemia Diseases 0.000 claims abstract description 35
- 206010028923 Neonatal asphyxia Diseases 0.000 claims abstract description 19
- 101710096361 Prostaglandin E synthase Proteins 0.000 claims description 236
- 102100033076 Prostaglandin E synthase Human genes 0.000 claims description 235
- 239000000126 substance Substances 0.000 claims description 195
- 238000012360 testing method Methods 0.000 claims description 193
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 158
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 151
- 229920001184 polypeptide Polymers 0.000 claims description 142
- 239000003112 inhibitor Substances 0.000 claims description 119
- 108090000623 proteins and genes Proteins 0.000 claims description 113
- 108010037462 Cyclooxygenase 2 Proteins 0.000 claims description 112
- 230000000694 effects Effects 0.000 claims description 110
- 241000124008 Mammalia Species 0.000 claims description 94
- 230000000241 respiratory effect Effects 0.000 claims description 87
- 206010021143 Hypoxia Diseases 0.000 claims description 75
- 230000014509 gene expression Effects 0.000 claims description 65
- 208000015181 infectious disease Diseases 0.000 claims description 50
- YIBNHAJFJUQSRA-YNNPMVKQSA-N prostaglandin H2 Chemical compound C1[C@@H]2OO[C@H]1[C@H](/C=C/[C@@H](O)CCCCC)[C@H]2C\C=C/CCCC(O)=O YIBNHAJFJUQSRA-YNNPMVKQSA-N 0.000 claims description 47
- 239000000758 substrate Substances 0.000 claims description 45
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 40
- 102100032752 C-reactive protein Human genes 0.000 claims description 39
- 238000004519 manufacturing process Methods 0.000 claims description 37
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 36
- 201000002859 sleep apnea Diseases 0.000 claims description 34
- 230000015572 biosynthetic process Effects 0.000 claims description 33
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 33
- 238000011282 treatment Methods 0.000 claims description 33
- 230000004913 activation Effects 0.000 claims description 30
- 230000007954 hypoxia Effects 0.000 claims description 29
- 229940111134 coxibs Drugs 0.000 claims description 27
- 230000001404 mediated effect Effects 0.000 claims description 27
- 208000024891 symptom Diseases 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 26
- 230000001146 hypoxic effect Effects 0.000 claims description 25
- 239000000556 agonist Substances 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- 230000002269 spontaneous effect Effects 0.000 claims description 24
- 201000010769 Prader-Willi syndrome Diseases 0.000 claims description 23
- 150000007523 nucleic acids Chemical class 0.000 claims description 23
- 210000002700 urine Anatomy 0.000 claims description 23
- 230000009870 specific binding Effects 0.000 claims description 22
- 238000003786 synthesis reaction Methods 0.000 claims description 22
- 208000035475 disorder Diseases 0.000 claims description 21
- 230000006735 deficit Effects 0.000 claims description 20
- 208000001797 obstructive sleep apnea Diseases 0.000 claims description 19
- 229940114079 arachidonic acid Drugs 0.000 claims description 18
- 235000021342 arachidonic acid Nutrition 0.000 claims description 18
- 102000039446 nucleic acids Human genes 0.000 claims description 18
- 108020004707 nucleic acids Proteins 0.000 claims description 18
- 208000004756 Respiratory Insufficiency Diseases 0.000 claims description 17
- 206010003497 Asphyxia Diseases 0.000 claims description 16
- 206010038678 Respiratory depression Diseases 0.000 claims description 15
- 230000007958 sleep Effects 0.000 claims description 15
- 208000034972 Sudden Infant Death Diseases 0.000 claims description 14
- 206010042440 Sudden infant death syndrome Diseases 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 14
- 125000004122 cyclic group Chemical group 0.000 claims description 13
- 230000005764 inhibitory process Effects 0.000 claims description 13
- 230000002829 reductive effect Effects 0.000 claims description 13
- 210000004369 blood Anatomy 0.000 claims description 12
- 239000008280 blood Substances 0.000 claims description 12
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 102000010907 Cyclooxygenase 2 Human genes 0.000 claims description 9
- 229940124639 Selective inhibitor Drugs 0.000 claims description 9
- 230000000737 periodic effect Effects 0.000 claims description 9
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical group CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 claims description 9
- 208000006289 Rett Syndrome Diseases 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 230000002458 infectious effect Effects 0.000 claims description 8
- 239000011230 binding agent Substances 0.000 claims description 7
- 230000009984 peri-natal effect Effects 0.000 claims description 7
- -1 5-bromo-2-methoxyphenyl Chemical group 0.000 claims description 5
- 206010010356 Congenital anomaly Diseases 0.000 claims description 5
- 230000036391 respiratory frequency Effects 0.000 claims description 5
- QAOAOVKBIIKRNL-UHFFFAOYSA-N 3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(propan-2-yl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid Chemical group OC(=O)C(C)(C)CC1=C(SC(C)(C)C)C2=CC(C(C)C)=CC=C2N1CC1=CC=C(Cl)C=C1 QAOAOVKBIIKRNL-UHFFFAOYSA-N 0.000 claims description 4
- 102000008866 Prostaglandin E receptors Human genes 0.000 claims description 4
- 108010088540 Prostaglandin E receptors Proteins 0.000 claims description 4
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims description 4
- 230000020874 response to hypoxia Effects 0.000 claims description 4
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 claims description 3
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims description 3
- 230000035945 sensitivity Effects 0.000 claims description 3
- 206010021133 Hypoventilation Diseases 0.000 claims description 2
- 229960000590 celecoxib Drugs 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229960000371 rofecoxib Drugs 0.000 claims description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 229960002004 valdecoxib Drugs 0.000 claims description 2
- ZKFOTVQFSMRKNU-UHFFFAOYSA-N 3-(4-methylsulfonylphenyl)-4-phenyl-2,5-dihydrofuran Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)COC1 ZKFOTVQFSMRKNU-UHFFFAOYSA-N 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 230000001960 triggered effect Effects 0.000 claims 1
- 230000037361 pathway Effects 0.000 abstract description 65
- 230000002401 inhibitory effect Effects 0.000 abstract description 33
- 238000000338 in vitro Methods 0.000 abstract description 12
- 239000003814 drug Substances 0.000 abstract description 10
- 238000012750 in vivo screening Methods 0.000 abstract description 3
- 101150053131 PTGER3 gene Proteins 0.000 description 213
- 241000699670 Mus sp. Species 0.000 description 132
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 102
- 210000000133 brain stem Anatomy 0.000 description 65
- 239000000523 sample Substances 0.000 description 55
- 239000000047 product Substances 0.000 description 49
- 238000003556 assay Methods 0.000 description 47
- 239000004055 small Interfering RNA Substances 0.000 description 45
- 125000003729 nucleotide group Chemical group 0.000 description 39
- 108020004459 Small interfering RNA Proteins 0.000 description 34
- 239000002773 nucleotide Substances 0.000 description 34
- 150000001875 compounds Chemical class 0.000 description 32
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 29
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 28
- 230000001965 increasing effect Effects 0.000 description 27
- 239000012634 fragment Substances 0.000 description 26
- 150000001413 amino acids Chemical group 0.000 description 25
- 230000027455 binding Effects 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 25
- 206010002660 Anoxia Diseases 0.000 description 21
- 241000976983 Anoxia Species 0.000 description 21
- 206010058490 Hyperoxia Diseases 0.000 description 21
- 230000007953 anoxia Effects 0.000 description 21
- 230000000222 hyperoxic effect Effects 0.000 description 21
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 20
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 20
- 150000003180 prostaglandins Chemical class 0.000 description 20
- 150000003384 small molecules Chemical class 0.000 description 20
- 206010061218 Inflammation Diseases 0.000 description 19
- 230000004054 inflammatory process Effects 0.000 description 19
- 108020004999 messenger RNA Proteins 0.000 description 19
- 230000007959 normoxia Effects 0.000 description 19
- 229910052760 oxygen Inorganic materials 0.000 description 19
- 239000013598 vector Substances 0.000 description 19
- 210000004556 brain Anatomy 0.000 description 18
- 238000005259 measurement Methods 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 18
- 230000007423 decrease Effects 0.000 description 17
- 230000004044 response Effects 0.000 description 17
- 102000004190 Enzymes Human genes 0.000 description 16
- 108090000790 Enzymes Proteins 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 16
- 210000005262 rostral ventrolateral medulla Anatomy 0.000 description 16
- 230000002485 urinary effect Effects 0.000 description 16
- 238000012544 monitoring process Methods 0.000 description 15
- 210000002569 neuron Anatomy 0.000 description 15
- 238000012216 screening Methods 0.000 description 15
- 239000011780 sodium chloride Substances 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 14
- 230000008499 blood brain barrier function Effects 0.000 description 14
- 210000001218 blood-brain barrier Anatomy 0.000 description 14
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 14
- 206010013975 Dyspnoeas Diseases 0.000 description 13
- 230000000295 complement effect Effects 0.000 description 13
- 230000034994 death Effects 0.000 description 13
- 231100000517 death Toxicity 0.000 description 13
- 238000001514 detection method Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 238000002347 injection Methods 0.000 description 13
- 238000013518 transcription Methods 0.000 description 13
- 230000035897 transcription Effects 0.000 description 13
- 102000004127 Cytokines Human genes 0.000 description 12
- 108090000695 Cytokines Proteins 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 12
- 108091027967 Small hairpin RNA Proteins 0.000 description 12
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 12
- 239000002953 phosphate buffered saline Substances 0.000 description 12
- 238000009423 ventilation Methods 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 230000003247 decreasing effect Effects 0.000 description 11
- 230000000926 neurological effect Effects 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 206010066131 Congenital central hypoventilation syndrome Diseases 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- 239000005557 antagonist Substances 0.000 description 10
- 230000033228 biological regulation Effects 0.000 description 10
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 208000000122 hyperventilation Diseases 0.000 description 10
- 229960000905 indomethacin Drugs 0.000 description 10
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 9
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 9
- 230000004064 dysfunction Effects 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- ZJAZCYLYLVCSNH-JHJVBQTASA-N prostaglandin E2-UM Chemical compound O[C@@H]1CC(=O)[C@H](CCC(O)=O)[C@H]1CCC(=O)CCCCC(O)=O ZJAZCYLYLVCSNH-JHJVBQTASA-N 0.000 description 9
- 210000000278 spinal cord Anatomy 0.000 description 9
- 230000001629 suppression Effects 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- 108090000994 Catalytic RNA Proteins 0.000 description 8
- 102000053642 Catalytic RNA Human genes 0.000 description 8
- 108010024636 Glutathione Proteins 0.000 description 8
- 241000282412 Homo Species 0.000 description 8
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 8
- 102100037346 Substance-P receptor Human genes 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000009368 gene silencing by RNA Effects 0.000 description 8
- 230000000870 hyperventilation Effects 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 238000004949 mass spectrometry Methods 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- 238000005173 quadrupole mass spectroscopy Methods 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 108091092562 ribozyme Proteins 0.000 description 8
- 235000000346 sugar Nutrition 0.000 description 8
- ZJAZCYLYLVCSNH-UHFFFAOYSA-N tetranor-prostaglandin E metabolite Natural products OC1CC(=O)C(CCC(O)=O)C1CCC(=O)CCCCC(O)=O ZJAZCYLYLVCSNH-UHFFFAOYSA-N 0.000 description 8
- 238000013519 translation Methods 0.000 description 8
- 108091006027 G proteins Proteins 0.000 description 7
- 102000030782 GTP binding Human genes 0.000 description 7
- 108091000058 GTP-Binding Proteins 0.000 description 7
- 108700008625 Reporter Genes Proteins 0.000 description 7
- 239000012190 activator Substances 0.000 description 7
- 230000002411 adverse Effects 0.000 description 7
- 230000006399 behavior Effects 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 7
- 238000009593 lumbar puncture Methods 0.000 description 7
- 230000036961 partial effect Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 description 6
- 241000283984 Rodentia Species 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000002596 correlated effect Effects 0.000 description 6
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 6
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 210000002889 endothelial cell Anatomy 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 230000030279 gene silencing Effects 0.000 description 6
- 229960003180 glutathione Drugs 0.000 description 6
- 230000001788 irregular Effects 0.000 description 6
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 6
- 230000011664 signaling Effects 0.000 description 6
- CUJMXIQZWPZMNQ-XYYGWQPLSA-N 13,14-dihydro-15-oxo-prostaglandin E2 Chemical compound CCCCCC(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O CUJMXIQZWPZMNQ-XYYGWQPLSA-N 0.000 description 5
- 102100036201 Oxygen-dependent coproporphyrinogen-III oxidase, mitochondrial Human genes 0.000 description 5
- 208000018737 Parkinson disease Diseases 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 206010041235 Snoring Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 229940109239 creatinine Drugs 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 210000004940 nucleus Anatomy 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 230000033764 rhythmic process Effects 0.000 description 5
- 230000003519 ventilatory effect Effects 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 4
- 201000004449 Diamond-Blackfan anemia Diseases 0.000 description 4
- 101001135391 Homo sapiens Prostaglandin E synthase Proteins 0.000 description 4
- 101000600903 Homo sapiens Substance-P receptor Proteins 0.000 description 4
- 108700011259 MicroRNAs Proteins 0.000 description 4
- 206010038669 Respiratory arrest Diseases 0.000 description 4
- 108091028664 Ribonucleotide Proteins 0.000 description 4
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000002222 downregulating effect Effects 0.000 description 4
- 238000004817 gas chromatography Methods 0.000 description 4
- 102000047789 human PTGES Human genes 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 239000002679 microRNA Substances 0.000 description 4
- 238000002552 multiple reaction monitoring Methods 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 238000010149 post-hoc-test Methods 0.000 description 4
- 230000002028 premature Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000001034 respiratory center Anatomy 0.000 description 4
- 239000002336 ribonucleotide Substances 0.000 description 4
- 125000002652 ribonucleotide group Chemical group 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- PXGPLTODNUVGFL-ZWAKLXPCSA-N 11-epi-prostaglandin F2alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-ZWAKLXPCSA-N 0.000 description 3
- 208000002333 Asphyxia Neonatorum Diseases 0.000 description 3
- 206010003591 Ataxia Diseases 0.000 description 3
- 206010006448 Bronchiolitis Diseases 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000005720 Glutathione transferase Human genes 0.000 description 3
- 108010070675 Glutathione transferase Proteins 0.000 description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 description 3
- 102000003777 Interleukin-1 beta Human genes 0.000 description 3
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 3
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 3
- 206010057190 Respiratory tract infections Diseases 0.000 description 3
- 206010042434 Sudden death Diseases 0.000 description 3
- 208000002365 Viral Bronchiolitis Diseases 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 230000002567 autonomic effect Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 206010008129 cerebral palsy Diseases 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 229960003624 creatine Drugs 0.000 description 3
- 239000006046 creatine Substances 0.000 description 3
- 230000002939 deleterious effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000007914 intraventricular administration Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 102000013415 peroxidase activity proteins Human genes 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 150000003212 purines Chemical class 0.000 description 3
- 150000003230 pyrimidines Chemical class 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000033287 response to anoxia Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 239000012086 standard solution Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000036962 time dependent Effects 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 2
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 2
- PXGPLTODNUVGFL-KMUYITALSA-N (z)-2,2,3,3-tetradeuterio-7-[(1r,2r,3s,5s)-3,5-dihydroxy-2-[(e,3s)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid Chemical compound OC(=O)C([2H])([2H])C([2H])([2H])C\C=C/C[C@H]1[C@@H](O)C[C@H](O)[C@@H]1\C=C\[C@@H](O)CCCCC PXGPLTODNUVGFL-KMUYITALSA-N 0.000 description 2
- HPZMWTNATZPBIH-UHFFFAOYSA-N 1-methyladenine Chemical compound CN1C=NC2=NC=NC2=C1N HPZMWTNATZPBIH-UHFFFAOYSA-N 0.000 description 2
- RFLVMTUMFYRZCB-UHFFFAOYSA-N 1-methylguanine Chemical compound O=C1N(C)C(N)=NC2=C1N=CN2 RFLVMTUMFYRZCB-UHFFFAOYSA-N 0.000 description 2
- FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 2
- OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 description 2
- DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 description 2
- ZJAZCYLYLVCSNH-VFBFAAMGSA-N 8-[(1r,2r,5r)-2-(2-carboxyethyl)-5-hydroxy-3-oxocyclopentyl]-2,2,3,3,4,4-hexadeuterio-6-oxooctanoic acid Chemical compound OC(=O)C([2H])([2H])C([2H])([2H])C([2H])([2H])CC(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1CCC(O)=O ZJAZCYLYLVCSNH-VFBFAAMGSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 108091032955 Bacterial small RNA Proteins 0.000 description 2
- 102100026189 Beta-galactosidase Human genes 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- 229940124638 COX inhibitor Drugs 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 208000032274 Encephalopathy Diseases 0.000 description 2
- 241000283074 Equus asinus Species 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010021079 Hypopnoea Diseases 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 206010037213 Psychomotor retardation Diseases 0.000 description 2
- 102100027609 Rho-related GTP-binding protein RhoD Human genes 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 102000030621 adenylate cyclase Human genes 0.000 description 2
- 108060000200 adenylate cyclase Proteins 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- 230000003281 allosteric effect Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 230000001977 ataxic effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 230000006406 biphasic response Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000012568 clinical material Substances 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 208000036970 congenital 1 with or without Hirschsprung disease central hypoventilation syndrome Diseases 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 230000007783 downstream signaling Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 238000010304 firing Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000003434 inspiratory effect Effects 0.000 description 2
- 238000000185 intracerebroventricular administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 229940118019 malondialdehyde Drugs 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000000414 obstructive effect Effects 0.000 description 2
- 230000005868 ontogenesis Effects 0.000 description 2
- 125000000962 organic group Chemical group 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 230000001124 posttranscriptional effect Effects 0.000 description 2
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 150000003166 prostaglandin E2 derivatives Chemical class 0.000 description 2
- 239000012429 reaction media Substances 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000011896 sensitive detection Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- VHRUMKCAEVRUBK-WKELIDJCSA-N (z)-7-[(1s,5e)-5-[(z)-oct-2-enylidene]-4-oxocyclopent-2-en-1-yl]hept-5-enoic acid Chemical compound CCCCC\C=C/C=C1\[C@@H](C\C=C/CCCC(O)=O)C=CC1=O VHRUMKCAEVRUBK-WKELIDJCSA-N 0.000 description 1
- SATCOUWSAZBIJO-UHFFFAOYSA-N 1-methyladenine Natural products N=C1N(C)C=NC2=C1NC=N2 SATCOUWSAZBIJO-UHFFFAOYSA-N 0.000 description 1
- HWPZZUQOWRWFDB-UHFFFAOYSA-N 1-methylcytosine Chemical compound CN1C=CC(N)=NC1=O HWPZZUQOWRWFDB-UHFFFAOYSA-N 0.000 description 1
- KUKJHGXXZWHSBG-GMPNNLDHSA-N 12-HHTrE Chemical compound CCCCCC(O)\C=C\C=C\C\C=C\CCCC(O)=O KUKJHGXXZWHSBG-GMPNNLDHSA-N 0.000 description 1
- KUKJHGXXZWHSBG-WBGSEQOASA-N 12S-HHTrE Chemical compound CCCCC[C@H](O)\C=C\C=C\C\C=C/CCCC(O)=O KUKJHGXXZWHSBG-WBGSEQOASA-N 0.000 description 1
- HLYBTPMYFWWNJN-UHFFFAOYSA-N 2-(2,4-dioxo-1h-pyrimidin-5-yl)-2-hydroxyacetic acid Chemical compound OC(=O)C(O)C1=CNC(=O)NC1=O HLYBTPMYFWWNJN-UHFFFAOYSA-N 0.000 description 1
- SGAKLDIYNFXTCK-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)methylamino]acetic acid Chemical compound OC(=O)CNCC1=CNC(=O)NC1=O SGAKLDIYNFXTCK-UHFFFAOYSA-N 0.000 description 1
- YSAJFXWTVFGPAX-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetic acid Chemical compound OC(=O)COC1=CNC(=O)NC1=O YSAJFXWTVFGPAX-UHFFFAOYSA-N 0.000 description 1
- LFWHFZJPXXOYNR-RQZCQDPDSA-N 2-[(3e)-6-fluoro-2-methyl-3-[(4-methylsulfanylphenyl)methylidene]inden-1-yl]acetic acid Chemical compound C1=CC(SC)=CC=C1\C=C/1C2=CC=C(F)C=C2C(CC(O)=O)=C\1C LFWHFZJPXXOYNR-RQZCQDPDSA-N 0.000 description 1
- SVBOROZXXYRWJL-UHFFFAOYSA-N 2-[(4-oxo-2-sulfanylidene-1h-pyrimidin-5-yl)methylamino]acetic acid Chemical compound OC(=O)CNCC1=CNC(=S)NC1=O SVBOROZXXYRWJL-UHFFFAOYSA-N 0.000 description 1
- XMSMHKMPBNTBOD-UHFFFAOYSA-N 2-dimethylamino-6-hydroxypurine Chemical compound N1C(N(C)C)=NC(=O)C2=C1N=CN2 XMSMHKMPBNTBOD-UHFFFAOYSA-N 0.000 description 1
- SMADWRYCYBUIKH-UHFFFAOYSA-N 2-methyl-7h-purin-6-amine Chemical compound CC1=NC(N)=C2NC=NC2=N1 SMADWRYCYBUIKH-UHFFFAOYSA-N 0.000 description 1
- KOLPWZCZXAMXKS-UHFFFAOYSA-N 3-methylcytosine Chemical compound CN1C(N)=CC=NC1=O KOLPWZCZXAMXKS-UHFFFAOYSA-N 0.000 description 1
- GJAKJCICANKRFD-UHFFFAOYSA-N 4-acetyl-4-amino-1,3-dihydropyrimidin-2-one Chemical compound CC(=O)C1(N)NC(=O)NC=C1 GJAKJCICANKRFD-UHFFFAOYSA-N 0.000 description 1
- OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 1
- MQJSSLBGAQJNER-UHFFFAOYSA-N 5-(methylaminomethyl)-1h-pyrimidine-2,4-dione Chemical compound CNCC1=CNC(=O)NC1=O MQJSSLBGAQJNER-UHFFFAOYSA-N 0.000 description 1
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
- CFGDUDUEDQSSKF-UHFFFAOYSA-N 5-butyl-1h-pyrimidine-2,4-dione Chemical compound CCCCC1=CNC(=O)NC1=O CFGDUDUEDQSSKF-UHFFFAOYSA-N 0.000 description 1
- RHIULBJJKFDJPR-UHFFFAOYSA-N 5-ethyl-1h-pyrimidine-2,4-dione Chemical compound CCC1=CNC(=O)NC1=O RHIULBJJKFDJPR-UHFFFAOYSA-N 0.000 description 1
- KELXHQACBIUYSE-UHFFFAOYSA-N 5-methoxy-1h-pyrimidine-2,4-dione Chemical compound COC1=CNC(=O)NC1=O KELXHQACBIUYSE-UHFFFAOYSA-N 0.000 description 1
- ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- QCRCBPQJIOLDSS-UHFFFAOYSA-N 5-pentyl-1h-pyrimidine-2,4-dione Chemical compound CCCCCC1=CNC(=O)NC1=O QCRCBPQJIOLDSS-UHFFFAOYSA-N 0.000 description 1
- JHEKLAXXCHLMNM-UHFFFAOYSA-N 5-propyl-1h-pyrimidine-2,4-dione Chemical compound CCCC1=CNC(=O)NC1=O JHEKLAXXCHLMNM-UHFFFAOYSA-N 0.000 description 1
- PLUDYDNNASPOEE-UHFFFAOYSA-N 6-(aziridin-1-yl)-1h-pyrimidin-2-one Chemical compound C1=CNC(=O)N=C1N1CC1 PLUDYDNNASPOEE-UHFFFAOYSA-N 0.000 description 1
- WRDFPHCRHWMZJL-UHFFFAOYSA-N 6-(methylamino)-7,9-dihydropurin-8-one Chemical compound CNC1=NC=NC2=C1NC(O)=N2 WRDFPHCRHWMZJL-UHFFFAOYSA-N 0.000 description 1
- CZJGCEGNCSGRBI-UHFFFAOYSA-N 6-amino-5-ethyl-1h-pyrimidin-2-one Chemical compound CCC1=CNC(=O)N=C1N CZJGCEGNCSGRBI-UHFFFAOYSA-N 0.000 description 1
- QHAZIWURUZYEQM-UHFFFAOYSA-N 6-amino-5-pentyl-1h-pyrimidin-2-one Chemical compound CCCCCC1=CNC(=O)N=C1N QHAZIWURUZYEQM-UHFFFAOYSA-N 0.000 description 1
- OJPWPQVMVIQVRH-UHFFFAOYSA-N 6-amino-5-propyl-1h-pyrimidin-2-one Chemical compound CCCC1=CNC(=O)N=C1N OJPWPQVMVIQVRH-UHFFFAOYSA-N 0.000 description 1
- CKOMXBHMKXXTNW-UHFFFAOYSA-N 6-methyladenine Chemical compound CNC1=NC=NC2=C1N=CN2 CKOMXBHMKXXTNW-UHFFFAOYSA-N 0.000 description 1
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
- 208000014825 Abnormal muscle tone Diseases 0.000 description 1
- 206010063292 Brain stem syndrome Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 101150071146 COX2 gene Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 208000003417 Central Sleep Apnea Diseases 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 208000031427 Foetal heart rate deceleration Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 240000005625 Gypsophila elegans Species 0.000 description 1
- 108090001102 Hammerhead ribozyme Proteins 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 108010034791 Heterochromatin Proteins 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- 206010022840 Intraventricular haemorrhage Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GWNVDXQDILPJIG-SHSCPDMUSA-N Leukotriene C4 Natural products CCCCCC=C/CC=C/C=C/C=C/C(SCC(NC(=O)CCC(N)C(=O)O)C(=O)NCC(=O)O)C(O)CCCC(=O)O GWNVDXQDILPJIG-SHSCPDMUSA-N 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 101001033286 Mus musculus Interleukin-1 beta Proteins 0.000 description 1
- SGSSKEDGVONRGC-UHFFFAOYSA-N N(2)-methylguanine Chemical compound O=C1NC(NC)=NC2=C1N=CN2 SGSSKEDGVONRGC-UHFFFAOYSA-N 0.000 description 1
- KTDZCOWXCWUPEO-UHFFFAOYSA-N NS-398 Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1CCCCC1 KTDZCOWXCWUPEO-UHFFFAOYSA-N 0.000 description 1
- 206010028947 Neonatal hypoxic conditions Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 229940123257 Opioid receptor antagonist Drugs 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 102000015433 Prostaglandin Receptors Human genes 0.000 description 1
- 108010050183 Prostaglandin Receptors Proteins 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 102000014450 RNA Polymerase III Human genes 0.000 description 1
- 108010078067 RNA Polymerase III Proteins 0.000 description 1
- 230000010757 Reduction Activity Effects 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 101710097909 Substance-P receptor Proteins 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 206010072731 White matter lesion Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- SRBFZHDQGSBBOR-STGXQOJASA-N alpha-D-lyxopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-STGXQOJASA-N 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 239000012911 assay medium Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 230000035565 breathing frequency Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000003491 cAMP production Effects 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 210000001326 carotid sinus Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 230000035572 chemosensitivity Effects 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 230000019113 chromatin silencing Effects 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 230000005574 cross-species transmission Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000002638 denervation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 210000004458 heterochromatin Anatomy 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000003140 lateral ventricle Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 description 1
- 238000012917 library technology Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000001006 meconium Anatomy 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- DJLUSNAYRNFVSM-UHFFFAOYSA-N methyl 2-(2,4-dioxo-1h-pyrimidin-5-yl)acetate Chemical compound COC(=O)CC1=CNC(=O)NC1=O DJLUSNAYRNFVSM-UHFFFAOYSA-N 0.000 description 1
- IZAGSTRIDUNNOY-UHFFFAOYSA-N methyl 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetate Chemical compound COC(=O)COC1=CNC(=O)NC1=O IZAGSTRIDUNNOY-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 208000004141 microcephaly Diseases 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000008111 motor development Effects 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- XJVXMWNLQRTRGH-UHFFFAOYSA-N n-(3-methylbut-3-enyl)-2-methylsulfanyl-7h-purin-6-amine Chemical compound CSC1=NC(NCCC(C)=C)=C2NC=NC2=N1 XJVXMWNLQRTRGH-UHFFFAOYSA-N 0.000 description 1
- FZQMZXGTZAPBAK-UHFFFAOYSA-N n-(3-methylbutyl)-7h-purin-6-amine Chemical compound CC(C)CCNC1=NC=NC2=C1NC=N2 FZQMZXGTZAPBAK-UHFFFAOYSA-N 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 230000007171 neuropathology Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000003401 opiate antagonist Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 238000003068 pathway analysis Methods 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 201000005936 periventricular leukomalacia Diseases 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 210000002442 prefrontal cortex Anatomy 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 229940127293 prostanoid Drugs 0.000 description 1
- 150000003814 prostanoids Chemical class 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000007420 radioactive assay Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000000754 repressing effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 239000003169 respiratory stimulant agent Substances 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000002644 respiratory therapy Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- DFEYYRMXOJXZRJ-UHFFFAOYSA-N sevoflurane Chemical compound FCOC(C(F)(F)F)C(F)(F)F DFEYYRMXOJXZRJ-UHFFFAOYSA-N 0.000 description 1
- 229960002078 sevoflurane Drugs 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229960003400 sulprostone Drugs 0.000 description 1
- UQZVCDCIMBLVNR-TWYODKAFSA-N sulprostone Chemical group O[C@@H]1CC(=O)[C@H](C\C=C/CCCC(=O)NS(=O)(=O)C)[C@H]1\C=C\[C@@H](O)COC1=CC=CC=C1 UQZVCDCIMBLVNR-TWYODKAFSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- ZEMGGZBWXRYJHK-UHFFFAOYSA-N thiouracil Chemical compound O=C1C=CNC(=S)N1 ZEMGGZBWXRYJHK-UHFFFAOYSA-N 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- 238000012033 transcriptional gene silencing Methods 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 210000001644 umbilical artery Anatomy 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/88—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/20—Oxygen containing
- Y10T436/200833—Carbonyl, ether, aldehyde or ketone containing
- Y10T436/201666—Carboxylic acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Food Science & Technology (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98721707P | 2007-11-12 | 2007-11-12 | |
| PCT/GB2008/003856 WO2009063226A2 (en) | 2007-11-12 | 2008-11-12 | Methods relating to breathing disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011503164A true JP2011503164A (ja) | 2011-01-27 |
| JP2011503164A5 JP2011503164A5 (enExample) | 2011-12-22 |
Family
ID=40342124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010533659A Pending JP2011503164A (ja) | 2007-11-12 | 2008-11-12 | 呼吸障害に関連する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20110008258A1 (enExample) |
| EP (1) | EP2219736A2 (enExample) |
| JP (1) | JP2011503164A (enExample) |
| CN (1) | CN102036713A (enExample) |
| CA (1) | CA2743334A1 (enExample) |
| WO (1) | WO2009063226A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101446873B1 (ko) | 2013-06-14 | 2014-10-06 | 서울대학교산학협력단 | 수면 무호흡증 진단용 생체 표지자 및 그 용도 |
| US20160124002A1 (en) * | 2013-06-14 | 2016-05-05 | Seoul National University R&Db Foundation | Method for detecting hypoxia or diagnosing hypoxia-related diseases |
| WO2016149344A1 (en) * | 2015-03-19 | 2016-09-22 | Inspire Medical Systems, Inc. | Stimulation for treating sleep disordered breathing |
| JP6885943B2 (ja) * | 2015-12-01 | 2021-06-16 | コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． | 失調性呼吸を治療する方法及び装置 |
| US11103159B2 (en) | 2016-03-04 | 2021-08-31 | United States Of America As Represented By The Secretary Of The Air Force | Exhaled breath hypoxia biomarkers |
| AU2019335070A1 (en) * | 2018-09-06 | 2021-05-13 | Ian Cooke | Method of treating a sleep breathing disorder |
| CN113376386B (zh) * | 2020-03-09 | 2025-09-02 | 中国科学院广州生物医药与健康研究院 | 一种病毒性肺炎的标志物及其应用 |
| CN115624626B (zh) * | 2022-08-15 | 2024-04-09 | 山东大学齐鲁医院 | Ep3受体在脊髓损伤后神经源性膀胱防治中的应用 |
| CN117323320B (zh) * | 2023-11-20 | 2025-10-31 | 复旦大学附属中山医院 | 长链脂肪酸12-hht在睡眠呼吸暂停合并高血压中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6601580B1 (en) * | 2000-06-28 | 2003-08-05 | The General Hospital Corporation | Enhancing therapeutic effectiveness of nitric oxide inhalation |
| CA2415697A1 (en) * | 2000-07-13 | 2002-01-24 | James C. Forbes | Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain |
| AU2003268032A1 (en) * | 2002-07-29 | 2004-02-16 | Epigenesis Pharmaceuticals, Inc. | Composition and methods for treatment and screening |
| WO2004078113A2 (en) * | 2003-03-04 | 2004-09-16 | Pharmacia Corporation | Treatment and prevention of obesity with cox-2 inhibitors alone or in combination with weight-loss agents |
| US20050107349A1 (en) * | 2003-07-24 | 2005-05-19 | Pharmacia Corporation | Method for the treatment or prevention of respiratory disorders with a cyclooxygenase-2 inhibitor in combination with a muscarinic receptor antagonist and compositions therewith |
| WO2005027853A2 (en) * | 2003-09-19 | 2005-03-31 | University Of Louisville Research Foundation Inc | Method for treating snoring and sleep apnea with leukotriene antagonists |
| FR2862873A1 (fr) * | 2003-12-01 | 2005-06-03 | Pf Medicament | Utilisation des acides gras polyinsatures omega 3 dans l'apnee du sommeil |
| WO2006019984A2 (en) * | 2004-07-15 | 2006-02-23 | Yale University | Compositions, methods and kits for the diagnosis and treatment of sudden infant death syndrome |
| DK1629850T4 (da) * | 2004-08-24 | 2013-07-01 | Nutricia Nv | Næringssammensætning indeholdende ufordøjelige oligosaccharider |
| WO2006033965A2 (en) * | 2004-09-16 | 2006-03-30 | The Trustees Of The University Of Pennsylvania | Nadph oxidase inhibition pharmacotherapies for obstructive sleep apnea syndrome and its associated morbidities |
| US7488291B2 (en) * | 2005-09-28 | 2009-02-10 | Medtronic, Inc. | Methods for detecting and monitoring sleep disordered breathing using an implantable medical device |
| US8076315B2 (en) * | 2005-10-14 | 2011-12-13 | The Board Of Trustees Of The University Of Illinois | Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists |
| US20100074896A1 (en) * | 2006-11-30 | 2010-03-25 | The Johns Hopkins University | Antagonists of pge2 ep3 receptors |
| US8071557B2 (en) * | 2007-06-13 | 2011-12-06 | Vivus, Inc. | Treatment of pulmonary hypertension with carbonic anhydrase inhibitors |
-
2008
- 2008-11-12 US US12/742,342 patent/US20110008258A1/en not_active Abandoned
- 2008-11-12 WO PCT/GB2008/003856 patent/WO2009063226A2/en not_active Ceased
- 2008-11-12 EP EP08849597A patent/EP2219736A2/en not_active Withdrawn
- 2008-11-12 CA CA2743334A patent/CA2743334A1/en not_active Abandoned
- 2008-11-12 CN CN2008801244097A patent/CN102036713A/zh active Pending
- 2008-11-12 JP JP2010533659A patent/JP2011503164A/ja active Pending
Non-Patent Citations (4)
| Title |
|---|
| JPN6013050939; Ｓｌｅｅｐ Ｍｅｄｉｃｉｎｅ ３ （２００２） ４４９-４５０ * |
| JPN6013050943; Ａｒｃｈ Ｄｉｓ Ｃｈｉｌｄ １９９２ ６７： ４４０-４４２ * |
| JPN6013050944; Ｃｈｅｓｔ． ２００６；１３０（１）：１４３-１４８ * |
| JPN6013050946; Ａｃｔａ Ｐａｅｄｉａｔｒ ８９： １３６４-８． ２０００ * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009063226A3 (en) | 2010-01-07 |
| CN102036713A (zh) | 2011-04-27 |
| EP2219736A2 (en) | 2010-08-25 |
| US20110008258A1 (en) | 2011-01-13 |
| CA2743334A1 (en) | 2009-05-22 |
| WO2009063226A2 (en) | 2009-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hussong et al. | Soluble pathogenic tau enters brain vascular endothelial cells and drives cellular senescence and brain microvascular dysfunction in a mouse model of tauopathy | |
| Torres-Torrelo et al. | Lactate sensing mechanisms in arterial chemoreceptor cells | |
| Shan et al. | Interactions of the histamine and hypocretin systems in CNS disorders | |
| Shimoda et al. | Partial HIF-1α deficiency impairs pulmonary arterial myocyte electrophysiological responses to hypoxia | |
| Reinalter et al. | Role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome | |
| US20110008258A1 (en) | Methods relating to breathing disorders | |
| Norcross et al. | Effects of adolescent fluoxetine treatment on fear-, anxiety-or stress-related behaviors in C57BL/6J or BALB/cJ mice | |
| Parsons et al. | Huntington disease | |
| Lui et al. | Older adults at greater risk for Alzheimer’s disease show stronger associations between sleep apnea severity in REM sleep and verbal memory | |
| JP2015520170A (ja) | 熱ショックタンパク質（ＨＳＰ）９０−βを調節することによる代謝症候群の治療方法 | |
| Anderson et al. | The endocannabinoid system impacts seizures in a mouse model of Dravet syndrome | |
| Santiago-Fernández et al. | Age-related decline of chaperone-mediated autophagy in skeletal muscle leads to progressive myopathy | |
| Li et al. | Cingulate retinoic acid signaling regulates neuropathic pain and comorbid anxiodepression via extracellular matrix homeostasis | |
| Francis et al. | Motor end plate innervation loss in diabetes and the role of insulin | |
| Toledo et al. | Medullary astrocytes mediate irregular breathing patterns generation in chronic heart failure through purinergic P2X7 receptor signalling | |
| Diniz et al. | Premature aging in serious mental illness | |
| Zhang et al. | Pontine norepinephrine defects in Mecp2-null mice involve deficient expression of dopamine β-hydroxylase but not a loss of catecholaminergic neurons | |
| Yuan et al. | MicroRNA-124-3p regulates NPY to affect appetite in individuals with depressive disorder | |
| Peyron et al. | Melanin concentrating hormone in central hypersomnia | |
| Xin et al. | E2F2 induces microglial activation and augments depressive-like behavior in mice by repressing PTPN6 transcription | |
| Qi et al. | Circ_0000215 aggravates cerebral ischemic vertigo by targeting miR-361-3p to promote neuroinflammation and apoptosis | |
| DK2705364T3 (en) | Screening procedure for analgesics | |
| Miyagishi et al. | Expression of microsomal prostaglandin E synthase-1 in the spinal cord in a transgenic mouse model of amyotrophic lateral sclerosis | |
| US10292980B2 (en) | GAPDH cascade inhibitor compounds and methods of use and treatment of stress induced disorders including mental illness | |
| Cannon et al. | Skeletal myofiber VEGF deficiency leads to mitochondrial, structural, and contractile alterations in mouse diaphragm |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111104 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20111104 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131022 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140114 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140121 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140930 |